Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA

Trial Profile

Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Olaparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PARTNER
  • Most Recent Events

    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 10 May 2017 Planned End Date changed from 15 May 2020 to 1 Jan 2032.
    • 02 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top